Market Overview

UPDATE: Brean Murray Carret Initiates Coverage on Ventrus Biosciences

Related VTUS
Midday Movers
US Stock Futures Signal Lower Start On Wall Street

Brean Murray Carret and Co. initiates coverage of Ventrus Biosciences (NASDAQ: VTUS) at a Buy rating and a price target of $30.

Brean Murray Carret and Co. comments, “We are initiating coverage of Ventrus Biosciences Inc. with a Buy rating, as we believe that VEN 309 has blockbuster potential, given its proven efficacy, large target market and the lack of competitive prescription hemorrhoid drugs. Our Buy rating and 12‐month target price of $30 are based on a DCF analysis using a 40% discount rate and a 6x multiple of the terminal value for the projected 2022 EBITDA of $936 million. Ventrus is focused on developing drugs for gastrointestinal indications. The company's lead drug candidate, VEN 309, has completed several Phase 2 trials in patients with hemorrhoids, and within weeks, Phase 3 data will be released that we believe will support approval. Ventrus' secondary product, VEN 307, has already succeeded in a European Phase 3 trial, and we look forward to the pivotal Phase 3 trial in the U.S. beginning enrollment in 2H12.”

VTUS closed at $10.04 on Wednesday.

Latest Ratings for VTUS

May 2014Cantor FitzgeraldMaintainsHold
Feb 2014William BlairDowngradesOutperformMarket Perform
Feb 2014Cantor FitzgeraldDowngradesBuyHold

View More Analyst Ratings for VTUS
View the Latest Analyst Ratings

Posted-In: Brean Murray CarretAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (VTUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→